ENXTPA:IPNPharmaceuticals
A Look At Ipsen (ENXTPA:IPN) Valuation After UBS Downgrade On Cabometyx Patent Risk
UBS’s move to downgrade Ipsen (ENXTPA:IPN) to neutral, citing the looming patent expiry of its oncology drug Cabometyx, has pushed the company’s revenue resilience and oncology focus into sharper focus for investors.
See our latest analysis for Ipsen.
Against UBS’s downgrade, Ipsen’s €129.3 share price sits on the back of an 11.37% year to date share price return. The 5 year total shareholder return of 93.01% points to momentum that has so far been resilient rather than accelerating.
If you...